SCHEMBL7035677

SCHEMBL7035677

Cn1c(=O)n(Cc2ccccc2)c(=O)c2cc(C(=O)OC3CCOC3)sc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 6/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
TSHR P16473 2/20 0.38
PTGER1 P34995 1/20 0.38
GAA P10253 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734171 0.95 HTR3E (0.41) TRPA1HTR3EHTR3BHTR3AHTR3D
SCHEMBL6727783 0.86 SCN1A (0.46) TRPA1HTR3EHTR3BHTR3AHTR3D
SCHEMBL6732873 0.85 HTR3E (0.44) TRPA1HTR3EHTR3BHTR3AHTR3D
SCHEMBL6531562 0.85 TRPA1 (0.44) TRPA1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6729978 0.83 HTR3E (0.39) TRPA1HTR3EHTR3BHTR3AHTR3D
SCHEMBL6730221 0.82 HTR3E (0.40) TRPA1HTR3EHTR3BHTR3AHTR3D
SCHEMBL6727925 0.81 BCHE (0.46) TRPA1ALDH1A1KDM4ECYP2D6CYP3A4
SCHEMBL6235401 0.81 KDM4E (0.54) TRPA1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6525287 0.81 KMT2A (0.41) TRPA1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6727774 0.80 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 TRPA1 3888/4885HTR3E 854/4885HTR3B 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.